Michigan Cancer Research Fund                                                                                            American Cancer Society
   
test tube  
   

Research Project Description from Jennifer Cash, PhD, 2014 MCRF Fellow

Project Name: Understanding Regulation of P-Rex1, an Enhancer of Metastatic Potential

One trademark of cancer is the ability of tumor cells to move to a remote site in the body and form another tumor in a process called metastasis. Cancer metastasis is a critical problem in cancer patients, as it causes the majority of cancer deaths. Currently, most anti-cancer drugs only work to inhibit cancer growth. Therefore, there is an important unmet need for therapeutics that inhibit the ability of cancer to metastasize. One molecule strongly linked to cancer progression and metastasis is the enzyme P-Rex1. Increased levels of P-Rex1 are associated with poor patient outcome in breast cancer and have been shown to facilitate metastasis of melanoma and prostate cancer cells. Therefore, P-Rex1 is an attractive target for the development of anti-metastasis drugs. However, the structure and the molecular basis for regulation of this enzyme by signaling lipids and cell surface receptors are not understood. Knowledge of these features will enable our long-term goal of developing selective chemical probes that could ultimately serve as therapeutic leads targeting P-Rex1.

Towards this goal, we have been using a technique called X-ray crystallography to determine atomic structures of fragments of P-Rex1 that reveal how certain molecules interact with it and increase its activity. In this proposal, we will fully describe the molecular details of how key regulators bind to the enzyme. These sites of interaction are "hotspots" that can be targeted by small molecule inhibitors with the goal of thwarting the ability of P-Rex1 to promote cell migration and thus suppressing cancer metastasis.

Summer 2016 Update

Over the last year, we have made significant progress toward understanding how P-Rex1 is regulated in the body. We have determined how a key regulator called PIP3 binds to P-Rex1 and that this binding is essential for turning on P-Rex1 activity. We have also identified other characteristics of P-Rex1 that may be important for its regulation in the body. This work is described in our recent publication in the journal Structure (doi:10.1016/j.str.2016.02.022). 

Our work has also been presented at both local and regional meetings, including the Experimental Biology meeting this spring in San Diego. At this meeting, I received a Postdoctoral Best Presentation Award from the Division for Molecular Pharmacology of the American Society for Pharmacology and Experimental Therapeutics. Since receiving an ACS/MCRF fellowship, I have enjoyed participating in a variety of ACS events. For example, I was invited to the University of Michigan women’s basketball annual Pink Game where I spoke on court during halftime about my research and my personal experience with breast cancer (http://www.lsi.umich.edu/research-highlights-7). I appreciate being able to join into these ACS events, as they bring together researchers and survivors as well as the people doing the fundraising, which is invaluable in reminding me why I do science on a daily basis.